Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 714032 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
ElectronicAdd to Basket



Success Principles: Making Pharmaceutical Business Development Fit for Purpose
Decision Resources, Inc., Dec 2007, Pages: 30


  Description  
  Table of Contents  
    
    
    
   
 Enquire before Buying  
 Send to a Friend  

Introduction:

In today’s competitive and evolving pharmaceutical landscape, Business Development is a strategic lifeline for all companies. The more successful Business Development departments share factors that clearly distinguish them from the pack. These success principles can be used by other companies to reinvent the role, direction, and operation of their Business Development functions so they, too, can be 'Fit for Purpose.'

Get the Answers You Need to Shape Your Strategy:

-Corporate management in successful pharmaceutical companies invariably recognizes and taps into Business Development’s understanding of the future and integrates Business Development’s thinking into strategy-formulation processes. What aspects of the pharmaceutical environment does pharmaceutical Business Development particularly need to understand in order to be successful?

-Most pharmaceutical companies have not seen Business Development as the future lifeblood of the company, and their Business Development groups are poorly equipped to take on this new strategic role. What are the most common shortcomings of Business Development departments? How are these shortcomings affecting pharmaceutical companies’ ability to succeed? How can companies best redirect and reorganize their Business Development departments?

-Partly as a result of Pharma’s lack of internally generated new products, product acquisitions have become increasingly important. What is the primary reason many pharmaceutical companies fail to acquire new products that they have targeted? What aspect of the product acquisition process do Business Development strategies need to focus on?

Scope:

-Business Development as an Indispensable Strategic Lifeline: the tools of Business Development

-The 1990s—Pharma Enters the Real World: technology changes and new customer economics

-Consolidation: the rumble that became a landslide; the view of pharmaceutical management; the effect on new product innovation

-The turn of the millennium: pressures mount; the seven key factors molding today’s landscape

-The industry’s schizophrenic approach to Business Development: the not invented here mind-set; Big Pharma sits up and finally takes notice; a shift in strategic outlook

What is wrong with today’s pharmaceutical Business Development?: the consequences of funding issues, unseasoned staff, and counterproductive internal relationships

Business Development success principles: key factors aiding the identification of customers’ future needs and desires; the evolution of Fit for Purpose and complex business strategies.

Key Concepts Mentioned:
- Advantage of scale
- Alliance management
- Brain babies
- Business intelligence
- Buying-in
- Cash cow brands
- Commercial threshold
- Company culture
- Competitive advantage
- Consolidation
- Copromotion
- Cost-cutting
- Cost-effectiveness
- Cultural mindset
- Customer economics
- Customer relevance
- Cycle time
- Decision-making process
- Developed markets
- Distribution deals
- Esoteric diseases
- Evidence-based medicine
- Feedback loops
- Fit for Purpose
- Fit with Strategy
- Fixed combinations
- Follow-on products
- Fully integrated pharmaceutical
companies (FIPCO)
- Generics substitution
- Genetic engineering
- “Go/no go” decision
- Health technology assessment
- Indigenous companies
- Inlicensing
- Innovation gap
- Joint ventures
- Knowledge networks
- Legacy practices
- Leverage
- Low-value brands
- Management and control
systems
- Market research
- Mergers & acquisitions
- “Me too” products
- Middle management
- Milestones
- Mittelstand
- Molecular differentiation
- Net Present Value (NPV)
- New molecular entities
(NMEs)
- Next-generation drugs
- Not invented here syndrome
- Organizational hierarchy
- Outlicensing
- Outsourcing
- Partner of Choice
- Patent expiry
- Pharmacogenomics
- Population aging
- Product acquisition
- Productivity decline
- Profi t-sharing mechanisms
- Program champion
- Proof of concept
- Protein-based therapeutics
- R&D productivity
- Range extension
- Relationship management
- Resource allocation
- Restructuring
- Revitalizing, repurposing, or
repositioning
- Risk avoidance
- Royalty obligations
- Short-term earnings
- Social networks
- Spin-offs
- Start-ups
- Technology gap
- Transformational change
- Translational block
- Up-front payments
- Value chain
- Value for money
- Venture capital



Customers who bought this item also bought

Specialty Pharma: Guide to Success at the New Frontier

Translational Medicine: Bridging Pharmaceutical Discovery And Development With IT (Review Report)

Innovative Strategies and Models for R&D Success: The Evolving Networked Pharma Company

Pharma Business Management in India

Pharma's Changing Business Strategies: Five Deadly Pharma Sins

Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential

The Pharmaceutical Industry 2008: Current and Future Trends and Strategic Issues Shaping Pharma

Pharmaceutical Sales Force Effectiveness Strategies: Evaluating Evolving Sales Models & Advanced Technology for a Customer Centric Approach

New Approaches to Pharma R&D: Evolving Strategies to Rejuvenate R&D Efficiency

Bio/Pharma R&D Statistical Sourcebook 2008/2009

The Rise of Mid-Sized Pharma

The Pharmaceutical Market Outlook to 2018: Key Threats and Opportunities for Big Pharma and its Responses to them



Top of page


   All rights reserved. � Copyright 2010 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds